Pharmaceuticals

Seventy five percent of employers reported being directly affected by opioids, often as contributing to workplace accidents, lost productivity, staffing issues, missed workdays, and increased care and leave costs.

In order to maximize the plans fiduciary responsibilities, a contract with appropriate terms and definitions must be in place to allow the plan to exercise their right to carve-out prior authorization.

Drugs used to treat chronic conditions are being tried on coronavirus patients; CVS wants to ensure there’s enough to go around.

As medication costs continue to rise, employers should implement these strategies to mitigate the financial burden of pharmaceutical prices.

A state-run generic drug program would allow buyers to pool their bargaining power.

Understanding how to choose a pharmacy benefit manager can be beneficial for lowering prescription drug costs.

Drugstore are trying to keep Amazon from wresting away their piece of the $333 billion prescription-drug industry.

DirectPath has integrated a pricing tool into its platform, allowing workers to better determine the cost of medication.

Benefit managers may need to review cost accumulator programs for specialty medications under recent regulations.

The president’s proposal would have prohibited drugmakers from paying rebates to PBMs in government programs such as Medicare.

Benefits consultants play a key role in preparing employers for how they should use point-of-sale rebates to lower healthcare costs.

Benefits consultants play a key role in preparing employers for how they should use point-of-sale rebates to lower healthcare costs.

Claims are astronomical. The first thing clients should do is cover prescription drugs under stop-loss insurance.

Claims are astronomical. The first thing employers should do is cover prescription drugs under stop loss insurance.

Initiatives like Amazon, JPMorgan Chase and Berkshire Hathaway’s Haven may be key to improving drug transparency, says one PBM CEO.

Initiatives like Amazon, JPMorgan Chase and Berkshire Hathaway’s Haven may be key to improving drug transparency, says one PBM CEO.

Under the proposal, safe-harbor protection would be allowed only for rebates on discounts offered directly to patients, and fixed-fee service arrangements between drugmakers and PBMs.

The more educated employees are about treatment options and their pricing, the more likely they'll be to better engage in healthcare.

The outrageous prices for exclusive medications are crippling our health plans and terrorizing families in pain.